Abstract Oxycodone has become
one of the most popular opioids in
the United States. It is superior to
morphine in oral absorption and bioavailability,
and similar in terms of
protein binding and lipophilicity.
Gender more than age influences
oxycodone elimination. Unlike morphine,
oxycodone is metabolized by
the cytochrome isoenzyme CYP2D6,
which is severely impaired by liver
dysfunction. Controlled-release (CR)
oxycodone has become one of the
most frequently utilized sustainedrelease
opioids in the United States.
Both its analgesic benefits and its
side effects are similar to those of
CR morphine. CR oxycodone is similar
to morphine and other opioids in
its abuse potential. Deaths attributable
to oxycodone are usually associated
with polysubstance abuse in
which oxycodone is combined with
psychostimulants, other opioids,
benzodiazepines or alcohol. Oxycodone’s
kappa receptor binding has
little role in abuse or addiction. The
cost of CR oxycodone is prohibitive
for most American hospices.